Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

Abstract Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to e...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Simone Lista, Bruno P. Imbimbo, Margherita Grasso, Annamaria Fidilio, Enzo Emanuele, Piercarlo Minoretti, Susana López-Ortiz, Juan Martín-Hernández, Audrey Gabelle, Giuseppe Caruso, Marco Malaguti, Daniela Melchiorri, Alejandro Santos-Lozano, Camillo Imbimbo, Michael T. Heneka, Filippo Caraci
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-07-01
coleção:	Journal of Neuroinflammation
Assuntos:	Alzheimer’s disease Neuroinflammation Biomarkers GFAP YKL-40 ATI(N) classification system
Acesso em linha:	https://doi.org/10.1186/s12974-024-03163-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!